GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » NonCurrent Deferred Liabilities

Zenith Capital (Zenith Capital) NonCurrent Deferred Liabilities : $0.00 Mil (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Zenith Capital's non-current deferred liabilities for the quarter that ended in . 20 was $0.00 Mil.

Zenith Capital NonCurrent Deferred Liabilities Historical Data

The historical data trend for Zenith Capital's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital NonCurrent Deferred Liabilities Chart

Zenith Capital Annual Data
Trend
NonCurrent Deferred Liabilities

Zenith Capital Quarterly Data
NonCurrent Deferred Liabilities

Zenith Capital NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Zenith Capital's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenith Capital (Zenith Capital) Business Description

Traded in Other Exchanges
N/A
Address
300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1
Website
Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines